ArticleThe oncologist2025
Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Sacituzumab-govitecan plus pembrolizumab: redefining first-line therapy in PD-L1-positive advanced triple-negative breast cancer.Translational cancer research · 2026Article
- First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States.Breast cancer research and treatment · 2026Article
- TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.Future oncology (London, England) · 2026Article
- Epicatechin Gallate Blocks GC/GR Signaling to Suppress Stress-Induced Myeloid Differentiation of HSPCs and Subsequent TNBC Metastasis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Carboplatin Is Associated with Changes in Components of the mACS omega · 2026Article
- A Pyrone Glucoside fromBiomolecules · 2026Article
- Observational
- Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL.ESMO real world data and digital oncology · 2026Article
- Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.Advances in therapy · 2026Article
- Explainable machine-learning prediction of overall and cancer-specific survival in adult triple-negative breast cancer using SEER: a comparative study of nomograms and random survival forests.Translational cancer research · 2026Article
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.Current oncology (Toronto, Ont.) · 2026Article
- Review
- Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results.Breast (Edinburgh, Scotland) · 2026Observational
- New Perspectives in the Management of Triple-Negative Breast Cancer.Breast care (Basel, Switzerland) · 2026Review
- Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.Oncology research · 2026Review
- High-Risk Node-Positive Hormone Receptor-Positive/HER2-Low Breast Cancer Relapse on Adjuvant Abemaciclib Treatment with ER Loss at Metastatic Recurrence: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- In silico design of a multi-epitope vaccine against the triple negative breast cancer.Scientific reports · 2025Article
- Clinical Significance of Nuclear Yin-Yang Overexpression Evaluated by Immunohistochemistry in Tissue Microarrays and Digital Pathology Analysis: A Useful Prognostic Tool for Breast Cancer.International journal of molecular sciences · 2025Article
- IBCar: Potent Orally Bioavailable MethylCancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis real-world study describes the treatment landscape evolution after targeted therapy approval and associated survival outcomes for previously untreated metastatic triple-negative breast cancer (mTNBC) in the United States. PATIENTS AND
methodsThis retrospective analysis used de-identified electronic health record-derived data of patients diagnosed with mTNBC (January 2011-July 2022; index date was first-line [1L] treatment start date). Patient characteristics, treatment patterns, real-world overall survival (rwOS), and time to next treatment or death (TTNTD) were determined. Outcomes before (2011-2017, early cohort) and after (2018-2022, late cohort) targeted therapy approval were evaluated.
resultsAmong 2004 eligible patients, 21% were classified as Black, 13% had Eastern Cooperative Oncology Group performance status ≥2, and 63% were diagnosed with recurrent disease; median age was 60 years. First-line chemotherapy-only (single- and multiple-agent chemotherapy) use decreased with the introduction of targeted therapies from 96% before 2018 to 65% between 2019 and 2022. From 2019, 33% of patients received programmed death-(ligand) 1 inhibitor-based regimen; ~2% received poly (ADP-ribose) polymerase inhibitors. Median 1L treatment duration was 2.6 months and this did not change over time. Of all 1L patients, 34% died before second-line (2L) and 51% subsequently received 2L treatment. Median (95% CI) 1L rwOS and TTNTD were 11.3 (10.7-12.0) months and 4.3 (4.1-4.6) months, respectively. Median 1L 5-year survival [95% CI] showed statistically significant but small improvement from the early (10.9 [10.3-11.6] months) to late cohort (11.9 [10.7-13.1] months; HR [95% CI], 0.87 [0.78-0.96]).
conclusionThis analysis demonstrated that, despite changes in care over time, survival improvements were not clinically meaningful; thus, a substantial unmet need for more efficacious treatments in previously untreated patients with mTNBC remains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.